Non-rising PSA but radiographic progression in men on treatment with enzalutamide

Posted on October 11, 2016 by Sitemaster

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , | 1 Comment »

The FDA’s “take” on pre-chemo approval of abiraterone in mCRPC

Posted on January 10, 2014 by Sitemaster

A new article in Clinical Cancer Research offers us insights into the US Food and Drug Administration’s thinking about the approval of abiraterone acetate for the treatment of chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: , , , , , | 1 Comment »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives